期刊文献+
共找到131篇文章
< 1 2 7 >
每页显示 20 50 100
Changes of c-fos and c-jun mRNA Expression in Angiotensin Ⅱ-induced Cardiomyocyte Hypertrophy and Effects of Sodium Tanshinone ⅡA Sulfonate 被引量:9
1
作者 周代星 梁黔生 +1 位作者 何雪心 占成业 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2008年第5期531-534,共4页
The changes of proto-oncogene c-fos and c-jun mRNA expression in angiotensin Ⅱ (AngⅡ)-induced hypertrophy and effects of sodium tanshinone ⅡA sulfonate (STS) in the primary culture of neonatal rat cardiomyocyte... The changes of proto-oncogene c-fos and c-jun mRNA expression in angiotensin Ⅱ (AngⅡ)-induced hypertrophy and effects of sodium tanshinone ⅡA sulfonate (STS) in the primary culture of neonatal rat cardiomyocytes were investigated. Twelve neonatal clean grade Wistar rats were selected. The cardiomyocytes were isolated, cultured and divided according to different treatments in the medium. The cardiomyocyte size was determined by phase contrast microscope, and the rate of protein synthesis was measured by [3H]-Leucine incorporation. The c-fos and c-jun mRNA expression in cardiomyocytes was detected by reverse transcription polymerase chain reaction (RT-PCR). It was found after cardiomyocytes were treated with AngⅡ for 30 min, the c-fos and c-jun mRNA expression in cardiomyocytes was increased significantly (P〈0.01). After treatment with AngⅡ for 24 h, the rate of protein synthesis in AngⅡ group was significantly increased as compared with control group (P〈0.01). After treatment with AngⅡ for 7 days, the size of cardiomyocytes in AngⅡ group was increased obviously as compared with control group (P〈0.05). After pretreatment with STS or Valsartan before AngⅡ treatment, both of them could inhibit the above effects of AngⅡ (P〈0.05 or P〈0.01). It was suggested that STS could ameliorate AngⅡ-induced cardiomyocyte hy- pertrophy by inhibiting c-fos and c-jun mRNA expression and reducing protein synthesis rate of cardiomyocytes. 展开更多
关键词 sodium tanshinone A sulfonate angiotensin cardiomyocyte hypertrophy C-LOS C-JUN
下载PDF
Protective Effect and Mechanism of Sodium Tanshinone ⅡA Sulfonate on Microcirculatory Disturbance of Small Intestine in Rats with Sepsis 被引量:9
2
作者 祝伟 吕青 +2 位作者 陈华文 王照华 钟强 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2011年第4期441-445,共5页
To explore the protective effect of sodium tanshinone ⅡA sulfonate(STS) on microcirculatory disturbance of small intestine in rats with sepsis,and the possible mechanism,a rat model of sepsis was induced by cecal l... To explore the protective effect of sodium tanshinone ⅡA sulfonate(STS) on microcirculatory disturbance of small intestine in rats with sepsis,and the possible mechanism,a rat model of sepsis was induced by cecal ligation and puncture(CLP).Rats were randomly divided into 3 groups:sham operated group(S),sepsis group(CLP) and STS treatment group(STS).STS(1 mg/kg) was slowly injected through the right external jugular vein after CLP.The histopathologic changes in the intestinal tissue and changes of mesenteric microcirculation were observed.The levels of tumor necrosis factor-α(TNF-α) in the intestinal tissue were determined by using enzyme-linked immunoabsorbent assay(ELISA).The expression of intercellular adhesion molecule-1(ICAM-1) in the intestinal tissue was detected by using immunohistochemisty and Western blot,that of nuclear factor κB(NF-κB) and tissue factor(TF) by using Western blot,and the levels of NF-κB mRNA expression by using RT-PCR respectively.The microcirculatory disturbance of the intestine was aggravated after CLP.The injury of the intestinal tissues was obviously aggravated in CLP group as compared with S group.The expression levels of NF-κB p65,ICAM-1,TF and TNF-α were upregulaed after CLP(P0.01).STS post-treatment could ameliorate the microcirculatory disturbance,attenuate the injury of the intestinal tissues induced by CLP,and decrease the levels of NF-κB,ICAM-1,TF and TNF-α(P0.01).It is suggested that STS can ameliorate the microcirculatory disturbance of the small intestine in rats with sepsis,and the mechanism may be associated with the inhibition of inflammatory responses and amelioration of coagulation abnormality. 展开更多
关键词 sodium tanshinone A sulfonate SEPSIS nuclear factor κB tumor necrosis factor-α intercellular adhesion molecule-1 tissue factor
下载PDF
Altered Erythrocyte Membrane Calcium Binding in Hypertensive Rats and the Effects of Sodium Tanshinone Ⅱ-A Sulphonate on It
3
作者 王幼林 汤国枝 +2 位作者 卢春林 丁建花 李德兴 《The Journal of Biomedical Research》 CAS 1994年第1期29-31,共3页
The calcium binding of erythrocyte membrane was determined in spontaneous hypertensiverats (SHR)and renovascular hypertensive rats (RVHR two-kidney, one-clip model) and the effect ofsodium tanshinone Ⅱ-A sulfonate(DS... The calcium binding of erythrocyte membrane was determined in spontaneous hypertensiverats (SHR)and renovascular hypertensive rats (RVHR two-kidney, one-clip model) and the effect ofsodium tanshinone Ⅱ-A sulfonate(DS-201)on the calcium binding in SHRs was investigated. Ourresults show that the basal calcium binding was reduced in SHRs (P<0.01 vs WKY),while the maximalcalcium binding was not,but both typies calcium bindings had no significant change in RVHRs.Sodiumtanshinone Ⅱ-A sulfonate (125μ mol/L)have no effect on the calcium binding of ecythrocyte membraneof SHR in vitro.These data further support the hypothesis that there is a cell membrane abnormalitypresent in SHRs which may possibly serve as a marker genetics of in hypertension. 展开更多
关键词 membrane calcium binding ERYTHROCYTE spontaneous hypertension renovascularhypertension rat sodium tanshinone -A sulfonate
下载PDF
Tanshinone ⅡA: an overview of its biological activity and the molecular mechanism 被引量:1
4
作者 Bin Zhao Yuan-Bo Wang +1 位作者 Xue-Ling Zheng Jun-Mei Dong 《TMR Theory and Hypothesis》 2018年第2期40-44,共5页
Danshen, the rhizome of Salvia miltiorrhiza Bunge, has been used in traditional Chinese medicine (TCM) for treatment of various diseases. Tanshinone IIA (TSA) is one of the main active components of Danshen, w... Danshen, the rhizome of Salvia miltiorrhiza Bunge, has been used in traditional Chinese medicine (TCM) for treatment of various diseases. Tanshinone IIA (TSA) is one of the main active components of Danshen, which has multiple bioactivities. This article reviews the research progress of TSA in the treatment of cardiovascular disease, anti-inflammatory and immune, anti-tumor, liver protection, neuroprotection. It provides more ideas for the clinical application of TSA and the development of drug resistance. 展开更多
关键词 DANSHEN tanshinone A sodium tanshinone IIA sulfonate
下载PDF
Sodium Tanshinone Ⅱ A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials 被引量:19
5
作者 TAN Di WU Jia-rui +2 位作者 ZHANG Xiao-meng LIU Shi ZHANG Bing 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2018年第2期156-160,共5页
Objective: To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection(STS) as one adjuvant therapy for treating unstable angina pectoris(UAP). Methods: Randomized contro... Objective: To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection(STS) as one adjuvant therapy for treating unstable angina pectoris(UAP). Methods: Randomized controlled trials(RCTs) of UAP treated by STS were searched in the China National Knowledge Infrastructure Database(CNKI), VIP Database for Chinese Technical Periodicals(VIP), Wanfang Database, the Chinese Biomedical Literature Database(CBM), Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results: The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine(WM) in the treatment of UAP can obviously improve the total effective rate [risk ratio(RR)=1.31, 95% confidence interval(CI)(1.24,1.39), P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI(1.30,1.56), P〈0.0001], decrease the level of CRP [mean difference(MD)=–3.06, 95%CI(–3.85, –2.27), P〈0.00001], fibrinogen [MD=–1.03, 95% CI(–1.16, –0.89), P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI(–0.92, –0.49), P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI(1.28, 9.94), P〈0.05]. Conclusions: Compared with WM, the combined use of STS was more effective. 展开更多
关键词 sodium tanshinone A sulfonate injection Chinese medicine unstable angina pectoris randomized controlled trials systematic review meta-analysis
原文传递
丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗死的临床研究 被引量:17
6
作者 徐丙超 周芯羽 +2 位作者 王轩 籍牛 董万利 《中国药房》 CAS 北大核心 2017年第26期3660-3663,共4页
目的:探讨丹参酮Ⅱ_A磺酸钠注射液对急性脑梗死患者血清P-选择素、胶质纤维酸性蛋白(GFAP)和血管内皮生长因子(VEGF)及神经功能的影响。方法:选择2013年4月-2016年4月连云港市第一人民医院收治的急性脑梗死患者114例,按随机数字表法分... 目的:探讨丹参酮Ⅱ_A磺酸钠注射液对急性脑梗死患者血清P-选择素、胶质纤维酸性蛋白(GFAP)和血管内皮生长因子(VEGF)及神经功能的影响。方法:选择2013年4月-2016年4月连云港市第一人民医院收治的急性脑梗死患者114例,按随机数字表法分为对照组与观察组,各57例。对照组患者给予常规治疗;观察组患者在对照组基础上加用丹参酮Ⅱ_A磺酸钠注射液40mg加入0.9%氯化钠注射液250 mL中,ivgtt,qd。7 d为1个疗程,两组均治疗2个疗程。比较两组患者治疗前和治疗7、14 d时的美国国立卫生院卒中量表(NIHSS)评分,血清P-选择素、GFAP和VEGF水平,以及不良反应发生情况。结果:治疗前,两组患者上述各项指标比较,差异均无统计学意义(P>0.05);与治疗前比较,两组患者治疗7、14 d时的NIHSS评分、血清P-选择素和GFAP水平均明显下降,血清VEGF水平明显上升,且治疗14 d时指标水平(NIHSS评分除外)均明显优于同组治疗7 d时,观察组指标水平均明显优于同期对照组,差异均有统计学意义(P<0.05)。两组患者均未见明显不良反应发生。结论:丹参酮Ⅱ_A磺酸钠注射液能显著降低急性脑梗死患者血清P-选择素和GFAP水平,提高VEGF水平,促进神经缺损功能恢复,且安全性较高。 展开更多
关键词 急性脑梗死 丹参酮A磺酸钠注射液 P-选择素 胶质纤维酸性蛋白 血管内皮生长因子 神经功能
下载PDF
基于Meta分析的丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗死临床评价研究 被引量:6
7
作者 刘施 吴嘉瑞 +3 位作者 段笑娇 张丹 张晓朦 张冰 《药物流行病学杂志》 CAS 2017年第12期803-808,共6页
目的:采用Meta分析方法评价丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗死的有效性及安全性。方法:计算机检索the Cochrane library、PubMed、Embase、SinoMed、中国知网、维普期刊数据库和万方数据库有关丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗... 目的:采用Meta分析方法评价丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗死的有效性及安全性。方法:计算机检索the Cochrane library、PubMed、Embase、SinoMed、中国知网、维普期刊数据库和万方数据库有关丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗死的随机对照试验,检索时限为各数据库建库至2016年10月。采用Cochrane风险评价表进行偏倚风险评价,提取资料通过Stata 13.1进行Meta分析。结果:最终共纳入13个随机对照试验,累计1 273名患者。Meta分析结果显示,对比西医常规治疗,丹参酮Ⅱ_A磺酸钠注射液辅助西医常规治疗急性脑梗死可提高临床总有效率(RR=1.22,95%CI:1.16~1.28,P<0.01),改善神经功能缺损(MD=-5.08,95%CI:-7.40^-2.77,P<0.01),降低炎性指标。在减少恶化情况方面,差异无统计学意义。有7篇文献明确无不良反应,2篇研究报道了共11例不良反应,其他文献均未对安全性做出说明,无严重不良反应。敏感性分析显示结果稳定性较好。结论:现有证据表明,丹参酮Ⅱ_A磺酸钠注射液治疗急性脑梗死在临床疗效、神经功能缺损改善及炎性指标减少等方面比单用西医常规疗效较好。但基于现有研究缺陷,所获得的支持证据强度有待提高,尚需要更多设计严谨、随访时间更长的临床研究予以证实。 展开更多
关键词 丹参酮A磺酸钠注射液 急性脑梗死 META分析
下载PDF
注射用丹参酮Ⅱ_A磺酸钠细菌内毒素检查法 被引量:3
8
作者 汤南 张丹 孙文霞 《时珍国医国药》 CAS CSCD 北大核心 2009年第10期2629-2630,共2页
目的建立检测注射用丹参酮ⅡA磺酸钠中内毒素的试验方法。方法运用干扰初筛法对供试品进行干扰试验,采用鲎试剂法对样品中的内毒素进行检测。结果注射用丹参酮ⅡA磺酸钠在药液稀释浓度为0.016 8 mg.m l-1以下时,与鲎试剂反应无干扰。结... 目的建立检测注射用丹参酮ⅡA磺酸钠中内毒素的试验方法。方法运用干扰初筛法对供试品进行干扰试验,采用鲎试剂法对样品中的内毒素进行检测。结果注射用丹参酮ⅡA磺酸钠在药液稀释浓度为0.016 8 mg.m l-1以下时,与鲎试剂反应无干扰。结论所采用的细菌内毒素检查法可用于注射用丹参酮ⅡA磺酸钠的内毒素检查。 展开更多
关键词 注射用丹参酮A磺酸钠 细菌内毒素检查法 干扰试验
下载PDF
丹参酮Ⅱ_A磺酸钠注射液与4种输液配伍的稳定性考察 被引量:5
9
作者 任汝仙 李雅琴 《中国药业》 CAS 2012年第13期4-5,共2页
目的考察丹参酮ⅡA磺酸钠与4种输液配伍后的稳定性。方法常温下将丹参酮ⅡA磺酸钠注射液分别与0.9%氯化钠注射液、10%葡萄糖注射液、葡萄糖氯化钠注射液、乳酸钠林格注射液配伍,分别在0,1,2,4,8,12 h时观察配伍溶液的外观、pH、不溶性微... 目的考察丹参酮ⅡA磺酸钠与4种输液配伍后的稳定性。方法常温下将丹参酮ⅡA磺酸钠注射液分别与0.9%氯化钠注射液、10%葡萄糖注射液、葡萄糖氯化钠注射液、乳酸钠林格注射液配伍,分别在0,1,2,4,8,12 h时观察配伍溶液的外观、pH、不溶性微粒,应用高效液相色谱法测定丹参酮ⅡA磺酸钠的含量。结果丹参酮ⅡA磺酸钠注射液与4种输液配伍12 h内溶液澄明,颜色无变化,无气泡产生,pH无明显变化,不溶性微粒检测符合中国药典要求。含量测定4 h后溶液主药浓度有所下降,但均大于95%,符合质量要求。结论丹参酮ⅡA磺酸钠注射液与4种输液在常温下、12 h内配伍稳定。 展开更多
关键词 丹参酮A磺酸钠注射液 输液 配伍稳定性
下载PDF
丹参酮Ⅱ_A磺酸钠注射液致变态反应的自动监测研究 被引量:1
10
作者 贾王平 郭代红 +2 位作者 寇炜 胡鹏洲 王啸宇 《药物流行病学杂志》 CAS 2017年第10期696-699,共4页
目的:利用"医疗机构ADE主动监测与智能评估警示系统"分析丹参酮Ⅱ_A磺酸钠注射液致变态反应的发生率及相关影响因素。方法:借助系统回顾性调取我院2014~2016年使用丹参酮Ⅱ_A磺酸钠注射液住院患者的病历,设置"变态反应&q... 目的:利用"医疗机构ADE主动监测与智能评估警示系统"分析丹参酮Ⅱ_A磺酸钠注射液致变态反应的发生率及相关影响因素。方法:借助系统回顾性调取我院2014~2016年使用丹参酮Ⅱ_A磺酸钠注射液住院患者的病历,设置"变态反应"与"过敏性休克"模块的事件配置器参数,分析系统阳性报警病例及各ADR发生率,并利用巢式病例对照研究设计,对丹参酮Ⅱ_A磺酸钠注射液致皮肤类变态反应的影响因素进行分析。结果:借助系统自动监测11 969例丹参酮Ⅱ_A磺酸钠注射液用药患者,用时约2 h;经临床药师再评估,皮肤类变态反应的发生率分别为0.15%,过敏样反应0.01%,无过敏性休克。丹参酮Ⅱ_A磺酸钠注射液致皮肤类变态反应在年龄、性别、过敏史、溶媒、BMI等方面差异无统计学意义。结论:专项软件系统可以高效快速进行丹参酮Ⅱ_A磺酸钠注射液致变态反应的自动监测,且能够初步预测其ADR相关影响因素,是中药注射剂上市后安全性再评价的好工具。 展开更多
关键词 丹参酮A磺酸钠注射液 变态反应 药品不良反应 自动监测
下载PDF
丹参酮Ⅱ_A磺酸钠注射液不良反应的流行病学特征研究 被引量:12
11
作者 王洪锐 李东 +1 位作者 翁浩聪 岳萱 《中国药业》 CAS 2014年第14期43-45,共3页
目的探讨丹参酮ⅡA磺酸钠注射液所致不良反应的流行病学特点,为临床安全用药提供参考。方法以"丹参酮""不良反应""安全性"等为检索词,检索中国医院知识仓库(CHKD)和万方数据库收录的1994年至2013年所有... 目的探讨丹参酮ⅡA磺酸钠注射液所致不良反应的流行病学特点,为临床安全用药提供参考。方法以"丹参酮""不良反应""安全性"等为检索词,检索中国医院知识仓库(CHKD)和万方数据库收录的1994年至2013年所有中文文献。阅读、筛选所有描述丹参酮ⅡA磺酸钠注射液不良反应的文献资料,按纳入和排除标准筛选后进行统计、分析。结果共检索报道丹参酮ⅡA磺酸钠注射液不良反应的文献22篇,收集其不良反应27例。丹参酮ⅡA磺酸钠注射液所致不良反应在高年龄组发生率较高;不良反应累及机体多个系统,临床表现复杂多样,主要表现为皮肤及其附件损害、全身性反应,严重者可出现过敏性休克。不良反应/事件多发生在给药后30 min以内,绝大多数经治疗后转归良好。结论丹参酮ⅡA磺酸钠注射液可致过敏性休克等严重不良反应,应提高临床合理用药水平,加强用药监护,以避免或减少不良反应的发生,保障患者用药安全。 展开更多
关键词 丹参酮A磺酸钠注射液 药品不良反应 文献分析 药物流行病学
下载PDF
18例丹参酮Ⅱ_A磺酸钠注射液不良反应的临床特点分析 被引量:18
12
作者 柳海琛 柳海环 《中国中西医结合杂志》 CAS CSCD 北大核心 2013年第9期1287-1289,共3页
目的探讨丹参酮ⅡA磺酸钠注射液不良反应的临床特点及其原因,为临床合理用药提供参考。方法检索丹参酮ⅡA磺酸钠注射液不良反应和配伍禁忌的文献报道(2000年1月—2011年12月国内医药学期刊),进行统计分析。结果 18例药品不良反应(advers... 目的探讨丹参酮ⅡA磺酸钠注射液不良反应的临床特点及其原因,为临床合理用药提供参考。方法检索丹参酮ⅡA磺酸钠注射液不良反应和配伍禁忌的文献报道(2000年1月—2011年12月国内医药学期刊),进行统计分析。结果 18例药品不良反应(adverse drug reaction,ADR)报告中,丹参酮ⅡA磺酸钠注射液不良反应的临床表现多样,皮肤及附件反应和神经肌肉系统反应各占50%,以老年人及女性为主,涉及器官系统多,存在诸多配伍禁忌。结论临床医务工作者应对丹参酮ⅡA磺酸钠注射液的不良反应引起高度重视,以避免不良反应的重复发生,规避风险,确保安全合理用药。 展开更多
关键词 丹参酮A磺酸钠 药品不良反应 临床特点
下载PDF
丹参酮Ⅱ_A磺酸钠注射液对冠心病不稳定型心绞痛血瘀证患者血小板活化功能的影响 被引量:22
13
作者 李荣军 张奎松 《中国药业》 CAS 2017年第10期63-66,共4页
目的探讨丹参酮Ⅱ_A磺酸钠注射液对冠状动脉粥样硬化性心脏病(简称冠心病)不稳定型心绞痛血瘀证及血小板活化功能的影响。方法选取2013年1月至2016年8月收治的冠心病不稳定性心绞痛血瘀证患者80例,采取单盲随机分组法分为两组,各40例,... 目的探讨丹参酮Ⅱ_A磺酸钠注射液对冠状动脉粥样硬化性心脏病(简称冠心病)不稳定型心绞痛血瘀证及血小板活化功能的影响。方法选取2013年1月至2016年8月收治的冠心病不稳定性心绞痛血瘀证患者80例,采取单盲随机分组法分为两组,各40例,对照组患者实施单纯西药治疗,观察组患者在对照组基础上加用丹参酮Ⅱ_A磺酸钠注射液治疗,治疗2周后,比较两组患者的临床总有效率、心绞痛发作次数、生活质量评分、血小板膜表面糖蛋白表达水平。结果观察组的临床总有效率为95.00%,明显高于对照组的80.00%(P<0.05);治疗后,两组患者的心绞痛发作次数均明显减少(P<0.05),且观察组治疗后的心绞痛发作次数明显低于对照组(P<0.05);观察组的生活质量评分明显高于对照组(P<0.05);相比于治疗前,两组患者治疗后的血小板膜糖蛋白CD63、PAC-1表达水平均明显上调(P<0.05),CD42b表达水平明显下调(P<0.05),且治疗后两组患者的血小板膜糖蛋白表达水平相比,差异有统计学意义(P<0.05)。结论丹参酮Ⅱ_A磺酸钠注射液治疗冠心病不稳定型心绞痛血瘀证临床疗效显著,可有效缓解心绞痛症状,抑制血小板活化功能,有利于改善患者的预后。 展开更多
关键词 冠状动脉粥样硬化性心脏病 不稳定型心绞痛 血瘀证 丹参酮A磺酸钠注射液 血小板活化功能
下载PDF
Effects of Tanshinone Combined with Western Medicine on Clinical Symptoms and Cardiac Function in Patients with Acute Heart Failure
14
作者 Liu Fang 《World Journal of Integrated Traditional and Western Medicine》 2019年第1期40-44,共5页
OBJECTIVE: To explore the effects of Tanshinone combined with western medicine on clinical symptoms and cardiac function in patients with acute heart failure. METHODS: The medical records of 96 patients with acute hea... OBJECTIVE: To explore the effects of Tanshinone combined with western medicine on clinical symptoms and cardiac function in patients with acute heart failure. METHODS: The medical records of 96 patients with acute heart failure were randomly divided into 2 groups(48 cases in observation group and 48 cases in control group). The control group was treated with conventional western medicine, and the observation group was treated with Tanshinone IIA sulfonic acid natrium on the basis of western medicine. The traditional Chinese medicine(TCM) syndromes scores before and after treatment(after 28 d of treatment), clinical efficacy, and cardiac echocardiographic indexes and serum biochemical indicators before and after treatment were observed in the 2 groups. RESULTS: After treatment, the scores of TCM syndromes in the 2 groups were significantly decreased(P < 0.05), and the change in observation group was significantly greater than that in control group(P < 0.05). The total clinical effective rate in observation group was significantly higher than that in control group(91.67% vs 75.00%)(P < 0.05). After treatment, the echocardiographic indexes of left ventricular end-diastolic diameter(LVEDD) and left ventricular end-systolic diameter(LVESD) values were significantly reduced in the 2 groups while the left ventricular ejection fraction(LVEF) and stroke volume(SV) value were significantly increased, and the changes in observation group were significantly larger than those in control group(P < 0.05). After treatment, the levels of serum nuclear factor-kappaB(NF-KB), interleukin-1β(IL-1β) and N-terminal pro-brain natriuretic peptide(NT-proBNP) were significantly decreased in the 2 groups(P < 0.05), while the 6-keto-prostaglandin F1α(6-ketoPGF1α) level was significantly increased. And the changes in observation group were significantly greater than those in control group(P < 0.05). CONCLUSION: Tanshinone combined with western medicine can significantly improve the clinical symptoms of patients with acute heart failure, improve cardiac function, reduce the myocardial damage degree, and effectively reduce the risk of short-term recurrence and death, and it has exact clinical efficacy. 展开更多
关键词 ACUTE HEART failure tanshinone A sulfonic acid NATRIUM Clinical SYMPTOMS CARDIAC function
下载PDF
Effect of Sodium Tanshinone ⅡA Sulfonate on Phosphorylation of Extracellular Signal-regulated Kinasel/2 in Angiotensin Ⅱ-induced Hypertrophy of Myocardial Cells 被引量:7
15
作者 李树生 冯俊 +1 位作者 郑智 梁黔生 《Chinese Journal of Integrative Medicine》 SCIE CAS 2008年第2期123-127,共5页
Objective: To observe the effects of sodium tanshinone ⅡA sulfonate (STS) on angiotensin Ⅱ (Ang Ⅱ)-induced hypertrophy of myocardial cells through the expression of phosphorylated extracellular signal-regulate... Objective: To observe the effects of sodium tanshinone ⅡA sulfonate (STS) on angiotensin Ⅱ (Ang Ⅱ)-induced hypertrophy of myocardial cells through the expression of phosphorylated extracellular signal-regulated kinase (p-ERK1/2). Methods: In the primary culture of neonatal rat myocardial cells, the total protein content in myocardial cells was determined by coomassie brilliant blue and the protein synthesis rate was measured by [3H]-Leucine incorporation as indexes for hypertrophy of myocardial cells. The expression of p-ERK1/2 was determined using Western blot and immunofluorescence labeling. Results: (1) The total protein and protein synthesis rate increased significantly in contrast to the control group after the myocardial cells were stimulated by Ang Ⅱ (1 μ mol/L) for 24 h; STS markedly inhibited the increment of the total protein level induced by Ang Ⅱ and the syntheses of protein. (2) After pretreatment of myocardial cells with Ang Ⅱ (1 μmol/L) for 5 min, the p-ERK1/2 protein expression was increased, with the most obvious effect shown at about 10 min; pretreatment of myocardial cells with STS at different doses (2, 10, 50μmol/L) for 30 min resulted in obvious inhibition of the expression of p-ERK1/2 stimulated by Ang Ⅱ in a dose-dependent manner. (3) After the myocardial cells were stimulated by AngⅡ (1 μ mol/L), the immunofluorescence of ERK1/2 rapidly appeared in the nucleus. The activation and translocation process of ERK1/2 induced by Ang Ⅱ was blocked distinctly by STS. (Conclusion: STS inhibited the myocardial cell hypertrophy induced by Ang Ⅱ, and the mechanism may be associated with the inhibition of p-ERK1/2 expression. 展开更多
关键词 sodium tanshinone A sulfonate angiotensin myocardial cell hypertrophy extracellular signal-regulated kinase
原文传递
Effect of Sodium Tanshinone ⅡA Sulfonate on Cardiac Myocyte Hypertrophy and Its Underlying Mechanism 被引量:6
16
作者 冯俊 郑智 《Chinese Journal of Integrative Medicine》 SCIE CAS 2008年第3期197-201,共5页
Objective: To investigate the effects of sodium tanshinone Ⅱ A sulfonate (STS) on the hypertrophy induced by angiotensin Ⅱ(Ang Ⅱ) in primary cultured neonatal rat cardiac myocytes. Methods: The effect of STS ... Objective: To investigate the effects of sodium tanshinone Ⅱ A sulfonate (STS) on the hypertrophy induced by angiotensin Ⅱ(Ang Ⅱ) in primary cultured neonatal rat cardiac myocytes. Methods: The effect of STS on cytotoxicity was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-3,5- phenytetrazoliumromide (MTT) assay. As indexes for cardiocyte hypertrophy, cell size was determined by phase contrast microscopy and protein synthesis rate was measured by 3H-leucine incorporation. The proto-oncogene c-fos mRNA expression of cardiocytes was assessed using reverse transcription polymerase chain reaction (RT-PCR). Results: STS could inhibit cardiocyte hypertrophy, increase the protein synthesis rate and enhance proto-oncogene c-fos mRNA expression in cardiocytes induced by Ang Ⅱ(P〈0.01), with an effect similar to that of Valsartan, the Ang Ⅱ receptor antagonist. Conclusion: STS can prevent the hypertrophy of cardiac myocytes induced by Ang Ⅱ, which may be related to its inhibition of the expression of proto-oncogene c-fos mRNA. 展开更多
关键词 sodium tanshinone A sulfonate angiotensin cardiac myocyte hypertrophy c-fos
原文传递
Sodium Tanshinone Ⅱ A sulfonate for acute myocardial infarction:a systematic review and Meta-analysis 被引量:4
17
作者 LIAN Baotao ZENG Ruixiang +3 位作者 LIAO Pengda GUO Liheng ZHANG Minzhou CHEN Yuanfang 《Journal of Traditional Chinese Medicine》 SCIE CSCD 2021年第1期26-35,共10页
OBJECTIVE: To investigate the efficacy and safety of Sodium tanshinone ⅡA sulfonate(STS) plus the conventional treatment on acute myocardial infarction(AMI) patients.METHODS: We searched several electrical databases ... OBJECTIVE: To investigate the efficacy and safety of Sodium tanshinone ⅡA sulfonate(STS) plus the conventional treatment on acute myocardial infarction(AMI) patients.METHODS: We searched several electrical databases and hand searched several Chinese medical journals up to January 2019. Randomized controlled trials(RCTs) comparing STS plus conventional treatment with conventional treatment were retrieved.Study screening, data extraction, quality assessment, and data analysis were conducted in accordance with the Cochrane standards.RESULTS: Sixteen trials involving 1383 people were included. The Meta-analysis showed STS combined with conventional treatment was a better treatment option than conventional treatment alone in reducing the risk of mortality, heart failure, arrhythmia and shock. In addition, STS was associated with improvement in left ventricular ejection fraction(LVEF) and left ventricular end diastolic dimension(LVEDD). No significant difference of STS was found on recurrent angina and recurrent AMI. However,the safety of STS remained uncertain for limited data.CONCLUSION: Compared with conventional treatment alone, STS combined with conventional treatment may provide more benefits for patients with AMI. Due to the fact that the overall quality of all included trials is generally low, further large-scale high quality trials are warranted. 展开更多
关键词 Myocardial infarction sodium tanshinoneA sulfonate Systematic review Metaanalysis
原文传递
丹参酮Ⅱ-A磺酸钠对纤维化人肾间质成纤维细胞体外增殖及cyclin E蛋白表达的影响 被引量:35
18
作者 孙兴旺 曹灵 +5 位作者 于国华 唐学清 郭庆喜 张弦 王巍 许凯 《第三军医大学学报》 CAS CSCD 北大核心 2007年第7期585-587,共3页
目的研究丹参酮Ⅱ-A磺酸钠(sodium tanshinoneⅡ-A sulfonate,DS-201)对人肾间质纤维化来源的成纤维细胞(human renal interstitial fibroblasts,hRIFs)体外增殖及细胞周期素E(cyclin E)基因表达的影响,探讨该药治疗肾间质纤维化的作用... 目的研究丹参酮Ⅱ-A磺酸钠(sodium tanshinoneⅡ-A sulfonate,DS-201)对人肾间质纤维化来源的成纤维细胞(human renal interstitial fibroblasts,hRIFs)体外增殖及细胞周期素E(cyclin E)基因表达的影响,探讨该药治疗肾间质纤维化的作用机制。方法体外培养并鉴定hRIFs;用四甲基偶氮唑(MTT)法检测对照组与不同DS-201浓度组hRIFs的增殖活性;用免疫细胞化学S-P法和图像分析技术检测对照组与不同DS-201浓度组hRIFs cyclin E基因的表达。结果随药物浓度的升高和作用时间的延长,抑制率逐渐升高,抑制作用逐渐增强,呈剂量依赖性和时间依赖性。用药组阳性细胞的平均光密度值在第3、5、7、9天显著低于对照组(P<0.05,P<0.01),第1天用药各组与对照组之间无统计学差异(P>0.05)。结论①DS-201对hRIFs体外增殖有显著抑制作用,可能是其治疗肾间质纤维化的机制之一。②DS-201抑制hRIFs体外增殖可能是通过抑制细胞中cyclin E基因的表达,阻滞细胞通过G1/S关卡,延长细胞周期实现的。 展开更多
关键词 丹参酮-A磺酸钠 肾脏 纤维化 成纤维细胞 细胞周期素E
下载PDF
丹参酮ⅡA磺酸钠和丹参素对猪冠状动脉平滑肌细胞钙激活钾通道的激活机制 被引量:39
19
作者 张洁 曾晓荣 +1 位作者 杨艳 刘智飞 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2005年第4期270-273,共4页
目的研究丹参酮ⅡA磺酸钠(DS-201)和丹参素(DS-182)的冠状动脉舒张作用除了已知的机制外,是否还与钙激活钾通道(KCa)有关。方法猪冠脉平滑肌细胞贴附式和内面向外式膜片钳单通道电流记录技术。结果DS-201和DS-182均可激活冠脉平滑肌细胞... 目的研究丹参酮ⅡA磺酸钠(DS-201)和丹参素(DS-182)的冠状动脉舒张作用除了已知的机制外,是否还与钙激活钾通道(KCa)有关。方法猪冠脉平滑肌细胞贴附式和内面向外式膜片钳单通道电流记录技术。结果DS-201和DS-182均可激活冠脉平滑肌细胞KCa,但DS-201在内面向外膜片方式下激活KCa;而DS-182在细胞贴附膜片方式下激活KCa。结论DS-201和DS-182激活KCa的作用机制不同。DS-201能直接激活KCa,而DS-182则可能需要一系列胞内过程。这种差异可能与二者的结构和溶解性质不同有关。 展开更多
关键词 丹参酮A磺酸钠 丹参素 钾通道 平滑 血管 冠状血管 膜片钳技术
下载PDF
丹参酮Ⅱa磺酸钠抑制巨噬细胞源性生长因子刺激平滑肌细胞c-myc基因表达 被引量:43
20
作者 张文军 包晓峰 +2 位作者 王秀凤 徐铭渔 钱振淮 《中国动脉硬化杂志》 CAS CSCD 1996年第1期45-47,共3页
本实验采用原位杂交技术,探讨丹参酮Ⅱa磺酸钠对血管平滑肌细胞增殖相关基因c-myc表达的影响。观察到巨噬细胞源性生长因子可明显促进平滑肌细胞c-myc高表达;丹参酮Ⅱa磺酸钠能阻止巨噬细胞源性生长因子刺激平滑肌细胞的... 本实验采用原位杂交技术,探讨丹参酮Ⅱa磺酸钠对血管平滑肌细胞增殖相关基因c-myc表达的影响。观察到巨噬细胞源性生长因子可明显促进平滑肌细胞c-myc高表达;丹参酮Ⅱa磺酸钠能阻止巨噬细胞源性生长因子刺激平滑肌细胞的作用,使c-myc表达水平下降,提示丹参酮Ⅱa磺酸钠可能在动脉粥样硬化疾病中阻止平滑肌细胞增殖起重要作用。 展开更多
关键词 丹参酮a 磺酸钠 平滑肌细胞 生长因子 CMYC
下载PDF
上一页 1 2 7 下一页 到第
使用帮助 返回顶部